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Abstract
Epigenetic changes in response to external stimuli are fast emerging as common underlying causes for the pre-disposition
to adult disease. Prenatal androgenization is one such model that results in reproductive and metabolic features that are
present in conditions such as polycystic ovary syndrome (PCOS). We examined the effect of prenatal androgens on liver
function and metabolism of adult sheep. As non-alcoholic fatty liver disease is increased in PCOS we hypothesized that this,
and other important liver pathways including metabolic function, insulin–like growth factor (IGF) and steroid receptivity,
would be affected. Pregnant ewes received vehicle control (C; n=5) or testosterone propionate (TP; n=9) twice weekly
(100 mg; i.m) from d62–102 (gestation 147 days). In a novel treatment paradigm, a second cohort received a direct C (n=4)
or TP (20 mg; n=7) fetal injection at d62 and d82. In adults, maternal TP exposure resulted in increased insulin secretion to
glucose load (P,0.05) and the histological presence of fatty liver (P,0.05) independent of central obesity. Additionally,
hepatic androgen receptor (AR; P,0.05), glucocorticoid receptor (GR; P,0.05), UDP- glucose ceramide glucosyltransferase
(UGCG; P,0.05) and IGF1 (P,0.01) expression were upregulated. The direct fetal intervention (C and TP) led to early fatty
liver changes in all animals without differential changes in insulin secretion. Furthermore, hepatic phosphoenolpyruvate
carboxykinase (PEPCK) was up-regulated in the fetal controls (P,0.05) and this was opposed by fetal TP (P,0.05). Hepatic
estrogen receptor (ERa; P,0.05) and mitogen activated protein kinase kinase 4 (MAP2K4; P,0.05) were increased following
fetal TP exposure. Adult liver metabolism and signaling can be altered by early exposure to sex steroids implicating
epigenetic regulation of metabolic disturbances that are common in PCOS.
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Introduction
An abnormal or altered fetal environment is emerging as a
likely etiological factor for a host of adult diseases [1,2]. The
maternal environment can influence epigenetic processes in the
placenta and fetus that program lasting developmental changes
associated with cardiovascular disease, hypertension, obesity, type
II diabetes, endocrine disruption and reproductive anomalies
[2,3,4], all of which are prevalent in Westernized societies.
Polycystic ovary syndrome (PCOS) is a common endocrine,
ovarian and metabolic disorder in young women and is proposed
to have early fetal origins [5,6]. Animal models of PCOS have
been established through investigation of the effects of increased
male sex hormone during pregnancy. Prenatal androgenization
of a female fetus results in the development of features
characteristic of PCOS in non-human primates, rats and sheep
[7,8,9,10,11]. Midgestation androgen exposure in sheep leads to
polyfollicular ovaries, increased luteinizing hormone (LH),
dysregulation of neuroendocrine feedback and ultimately dis-
rupted estrous cycles in adult offspring [11,12,13]. Metabolic
parameters such as hyperinsulinemia and insulin resistance are
also reported [14,15].
We hypothesized that the prenatal androgenization ovine
model, leading to adult reproductive and metabolic defects, could
inform us about early tissue-specific molecular changes associated
with the PCOS-like phenotype, with particular focus on the liver.
Women with PCOS are more likely to have abnormal levels of
liver function determinants [16,17] and non-alcoholic fatty liver
disease (NAFLD) [18,19,20]. NAFLD occurs through liver
damage, steatosis and in severe cases hepatic inflammation, and
is associated with central obesity and insulin resistance [21].
Women with PCOS have biochemical features of hyperandrogen-
ism [6], and androgens have a direct link with the development of
central obesity and insulin resistance [22,23]. Thus the metabolic
features of PCOS involve a complex interplay between increased
androgen concentrations, insulin signaling, central obesity and
NAFLD [6,24].
An assessment of NAFLD in young adult ewes exposed to
increased androgen concentrations in utero, and investigation of the
metabolic and synthetic function of the liver at a molecular level,
was carried out. The relationship between these findings and
changes in androgens, insulin resistance and central obesity was
determined to provide novel insights into possible early hepatic
alterations associated with a PCOS-like condition. We aimed to
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the development of NAFLD or clinical determinants of liver
damage, 2) is linked to the development of central obesity and
increased circulating androgen concentrations and, 3) results in a
metabolic phenotype affecting glucose and insulin homeostasis.
We investigated whether prenatal androgenization affected adult
liver function by examining the molecular expression of: 4) hepatic
steroid receptors, 5) the gluconeogenic enzyme phosphoenolpyr-
uvate carboxykinase (PEPCK) and other genes involved in
metabolic function, and 6) growth factor secretion by analyzing
hepatic expression of insulin-like growth factor 1 (IGF1).
Finally, we introduced a novel direct fetal intervention to assess
the effect of prenatal androgens on the adult hepatic phenotype
avoiding interference from placental aromatization of testosterone
[25] or the maternal effects of androgens. Young adult ewes were
directly injected with depot testosterone at d62 and d82 of
gestation and compared to those exposed to androgen from d62 to
d102 using conventional maternal administration of testosterone.
The timings of direct fetal injection were chosen to coincide with
the period of increased maternal androgens encountered by the
indirect treatment cohort.
Herein, we report the metabolic consequences of prenatal
androgenization that include fatty liver and perturbed insulin
signaling in young adult offspring, as well as intrinsic alterations in
hepatic gene expression that may contribute to the overall
metabolic phenotype observed in these animals. The direct
treatment paradigm resulted in differential effects on hepatic
outcome and insulin response compared to the indirect treatment
some of which were also regulated by androgens, indicating
programming by alternate pathways.
Results
Maternal prenatal androgenization is associated with
subclinical fatty liver in adults that is not related to
central obesity
To determine whether maternal prenatal androgenization is
associated with the development of fatty liver in young adult sheep,
liver tissue was examined for signs of lipid accumulation and plasma
was analyzed for clinical features of liver damage. An oil red O
histological lipid stain was performed on frozen liver sections and
staining was classified into negative (-), possible early (+/2), or
positive (+) fatty liver (Fig. 1A), as determined by the presence of red
lipid globules. Androgenization of female fetuses by maternal
testosterone propionate (TP) treatment from d62–102 of gestation
resulted in the presence of fatty liver in offspring at 11 months of age
(Fig. 1B; P,0.05). These early signs of liver damage were not
howeverdetectableataclinicallevelastherewasnochangeinserum
determinants of liver function including circulating aspartate
transaminase (AST; Fig. 1C), alanine transaminase (ALT;
C=19.462.8 U/l Vs TP=16.661.1 U/l), alkaline phosphatase
(ALP; C=179.8623.9 U/l Vs TP=200.1629.4 U/l) and gamma
glutamyltransferase (GGT; Fig. 1D) concentrations. Whilst fat
accumulation waspresentinthe liver,prenatal testosterone exposure
did not lead to increased body weight (Fig. 1E) or central obesity
(omental fat; Fig. 1F) in adult sheep. These findings were consistent
with the lack of change in circulating leptin concentrations (Fig. 1G).
Insulin homeostasis in maternally treated adult offspring
The presence of fatty liver without central obesity in adults from
androgenized mothers indicates early metabolic disruption that
might be further manifested systemically. Glucose tolerance tests
(GTTs) were carried out just prior to sacrifice to determine
pancreatic response to glucose. Following bolus glucose adminis-
tration, initial glucose dynamics between control and TP-exposed
animals were not altered (Fig. 1H), however glucose-stimulated
insulin secretion was significantly greater in the treatment group
(Fig. 1I; P,0.05), suggesting a perturbed pancreatic response. Basal
circulatinginsulin levels were higher in adults maternally exposed to
TP (Fig. 1I), though this did not reach statistical significance
(P=0.071). Other metabolic parameters including plasma free fatty
acids (FFA; C=0.7460.41 mmol/l Vs TP=0.6060.17 mmol/l),
triglycerides (C=0.360.07 mmol/l Vs TP=0.2860.02 mmol/l)
and cholesterol (Fig. 1J) were not altered.
Alterations in the expression of hepatic steroid receptors
As subclinical fatty liver, and insulin resistance, can be associated
with increased androgens we examined androgen concentrations
and the potential of the adult liver to respond to androgen. There
was no change in circulating testosterone concentrations in young
adults after maternal TP exposure (Fig. 2A). Unfortunately, suitable
assays for sex hormone binding globulin (SHBG) in the sheep were
not available to measure free androgen index. However, mRNA
analysis did not reveal significant changes in SHBG transcript
abundance (C=1.4660.17 Vs TP=2.0860.32). Androgen recep-
tor (AR) was found to be expressed in the nuclei and more weakly in
the cytoplasm of hepatocytes across the parenchymal region
(Fig. 2B), as well as in the nuclei of cells associated with portal
veins (arrow;Fig.2B). Interestingly, whilst a strong nuclear stain was
observed in many hepatocytes, a large proportion of cell nuclei were
alsonegative forAR (arrow;Fig.2C). This patterndidnot appearto
be altered by prenatal androgens. QRT-PCR analysis revealed an
upregulation of AR in the livers of prenatally TP-exposed adult
sheep (Fig. 2D; P,0.05). There was no difference in expression of
genomic estrogen receptors (ERa; Fig. 2E) but there was a small
increase in the hepatic expression of glucocorticoid receptors (GR;
Fig. 2F; P,0.05).
Functional changes in the adult liver
To determine whether there were functional changes in the liver
itself that may be associated with metabolic dysregulation we
investigated the effect of prenatal androgens on hepatic gluconeo-
genesis by examining liver PEPCK expression. Immunolocaliza-
tion of PEPCK (Fig. 3A) revealed widespread protein expression
throughout parenchymal liver tissue with positive staining
visualized within the cytoplasm and membrane of hepatocytes
particularly in the peri-portal region. The liver capsule, comprising
connective tissue, was negative for PEPCK (arrow; Fig. 3A) as
were the non-hepatocyte cells surrounding the hepatic portal vein
(HPV; arrow; Fig. 3B). However, there were no changes in PEPCK
expression in prenatally TP-treated animals (Fig. 3C). Other
candidate genes involved in metabolic function in the liver,
including mitogen activated protein kinase kinase 4 (MAP2K4),
UDP- glucose ceramide glucosyltransferase (UGCG) and acyl-
coenzyme A dehydrogenase (ACADM) were studied. Maternal
androgenization resulted in a 2-fold increase in hepatic MAP2K4
(Fig. 3D; trend) and upregulation of UGCG (Fig. 3E; P,0.05),
whereas ACADM mRNA was not altered by treatment (Fig. 3F).
There were also transcriptional differences in the components of
hepatic IGF system in prenatal TP-exposed adults, in which IGF1
was upregulated ,3-fold (Fig. 3G; P,0.01) without any significant
change in IGFBP1 expression (Fig. 3H) or IGF1R (Fig. 3I).
Fetal exposure to testosterone per se might not be
responsible for the subclinical fatty liver change
To assess the programming effects of prenatal androgenization
without maternal effects or the contribution of placental metabolism
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24877of TP, metabolic and liver outcomes were also investigated in adult
offspring directly treated with depot TP or vehicle control by
ultrasound-guided injection at d62a n dd 8 2o fg e s t a t i o n .T h e r ew a s
no difference in the proportion of adult animals histologically
categorizedforfatty liverbetweenTP treatmentandcontrol (Fig.4A).
In fact, and unexpectedly, all animals showed signs of possible, or
positive lipid accumulation (Fig. 4A) and the prevalence of fatty liver
was similar to maternal TP exposed animals rather than maternal
control injection animals. Nevertheless, like the maternal treated
cohorts, liver function determinants including serum AST (Fig. 4B),
ALT (C=17.561.7 U/l Vs TP=15.361.7 U/l), ALP (C=247.36
30.3 U/l Vs TP=197.6619.7 U/l) and GGT (Fig. 4C) were not
altered by direct fetal androgenization. In addition, there were no
differences in body weight (Fig. 4D), central obesity (omental fat;
Fig. 4E) or circulating leptin concentrations (Fig. 4F).
Insulin homeostasis in direct fetally treated adult
offspring
There were no significant differences between direct fetal control
and TP animals when glucose (Fig. 4G) and insulin (Fig. 4H) levels
were determined by GTT in adult animals. This suggests that fetal
TP exposure does not directly affect insulin homeostasis. However,
like the changes in hepatic lipid content, the direct fetal intervention
alone also affected insulin secretion in response to glucose load.
Although baseline glucose was similar in the fetal and maternal
treatment groups, 15 min after a glucose bolus the serum glucose
concentrations in the fetal treatment group were approximately
doublethoseofthematernaltreatment group(23.166.3 mmol/lVs
11.962.3 mmol/l, respectively; P=0.06). In addition, the fetal
control insulin concentrations after 15 min were mid-way between
the maternal control and TP treatments (Fig. 4H, Fig. 1I). Like the
Figure 2. Effect of maternal prenatal androgenization on adult liver steroid receptor expression. A) There was no difference in adult
plasma testosterone after maternal TP compared to controls. B–C) Immunohistochemistry showing androgen receptor (AR) localization in adult ovine
liver sections (B, scale bar=100 mm; arrow indicating staining in blood vessels and C, scale bar=20 mm; arrow indicating negatively stained
hepatocyte nucleus). Representative sections were selected from control animals. QRT-PCR showing the effect of maternal androgenization on
hepatic AR (D), ERa (E) and GR (F) mRNA expression. Values represent mean 6 SEM and *=P,0.05.
doi:10.1371/journal.pone.0024877.g002
Figure 1. Effect of maternal prenatal androgenization on adult liver lipid content and other metabolic parameters. A) Representative
oil red O histological stains for lipids in ovine adult liver sections illustrating negative (-), possible early (+/2) or positive (+) fatty liver (scale
bars=50 mm) and B) analysis of control (C; n=5) and maternal TP (n=9) showing increased fatty liver in the TP cohort. Maternal prenatal TP
treatment had no effect on adult liver analytes including aspartate transaminase (AST; C) and gamma glutamyltransferase (GGT; D). There was no
effect on body weight (E), weight of omental fat (F), plasma leptin (G) and cholesterol levels (J). H) Plasma glucose concentrations at basal levels and
15 min after i.v. glucose bolus showed no differences, however, after 15 min there were significantly higher plasma insulin concentrations in the TP
group (I). Values are mean 6 SEM and *=P,0.05.
doi:10.1371/journal.pone.0024877.g001
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result in a metabolic phenotype that is not changed by the presence
of testosterone and may affect glucose and insulin regulation. There
were no changes in circulating FFA (C=0.5260.03 mmol/l Vs
TP=0.5060.04 mmol/l), triglyceride (C=0.3260.06 mmol/l
Vs TP=0.2060.04 mmol/l) or cholesterol concentrations (Fig. 4I).
Alterations in the expression of hepatic steroid receptors
There were no differences in adult serum androgen concentra-
tions after direct fetal treatment with TP (C=42.8613.1 pg/ml
Vs TP=42.665.51 pg/ml). SHBG mRNA expression was also
unaltered (C=1.2760.15 Vs TP=1.1260.16). Unlike the
maternal TP-treatment cohort hepatic AR gene expression was
Figure 3. Effect of maternal prenatal androgenization on hepatic metabolic and signaling pathways. A-B) Immunohistochemistry for
PEPCK (brown) in adult liver sections. A) Hepatocytes are stained while supporting tissue, such as the capsule (arrow) are not immunostained (scale
bar=100 mm). B) Higher power section of the more intensely stained hepatocytes around the hepatic portal vessels (HPV). Arrow indicates no
staining associated with the non-hepatocytes in this region (scale bar=20 mm). Representative sections were selected from control animals. QRT-PCR
showing the effect of maternal androgenization on hepatic PEPCK (C), MAP2K4 (D), UGCG (E), ACADM (F), IGF1 (G), IGFBP1 (H) and IGF1R (I) mRNA
expression. Values represent mean 6 SEM and *=P,0.05, **=P,0.01.
doi:10.1371/journal.pone.0024877.g003
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tendency to be reduced. However, it was noted that AR mRNA
expression in fetal controls was in fact 3 times that of maternal
controls (2.160.70 Vs 0.6760.12, respectively; P=0.11). Also, in
contrast to the maternal treatment, direct fetal TP treatment led to
the upregulation of ERa gene expression in adult livers (Fig. 5B;
P,0.05). No change in hepatic GR mRNA expression was
observed in these animals (Fig. 5C).
Figure 4. Effect of direct fetal androgenization on metabolic parameters in adult offspring. A) There was no difference on the
development of fatty liver between control (C; n=4) and TP (n=7) administration. Fetal prenatal TP treatment did not affect adult liver analytes
including AST (B) and GGT (C). There was no effect on body weight (D), weight of omental fat (E) and plasma leptin (F) and cholesterol levels (I).
Plasma glucose (G) and insulin (H) concentrations at basal levels and 15 min after i.v. glucose bolus showed no differences. Values are mean 6 SEM.
doi:10.1371/journal.pone.0024877.g004
In Utero Programming of Metabolic Dysregulation
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24877Figure 5. Effect of direct fetal androgenization on molecular liver function in adult offspring. QRT-PCR showing the effect of prenatal
fetal androgenization on hepatic AR (A), ERa (B), GR (C), PEPCK (D), MAP2K4 (E), UGCG (F), ACADM (G), IGF1 (H) and IGFBP1 (I) mRNA expression. Values
represent mean 6 SEM and *=P,0.05.
doi:10.1371/journal.pone.0024877.g005
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Adult liver PEPCK mRNA expression was downregulated
following direct fetal TP exposure (Fig. 5D; P,0.05), in contrast
to findings in the maternal androgenized cohort. However, the
phenotypic effect of in utero injection was once more highlighted by
a significant upregulation of PEPCK mRNA levels in fetal control
compared to maternal control (354.4671.6 Vs 125.665.2,
respectively; P,0.05). Similarly to the findings in the maternal
TP cohort hepatic metabolic genes were increased in response to
fetal androgenization. MAP2K2 was upregulated 4-fold (Fig. 5E;
P,0.05) and both UGCG (Fig. 5F) and ACADM (Fig. 5G) tended to
increase so that the average mean transcript abundance in TP-
exposed animals was twice that of controls. In contrast to maternal
treatment, direct prenatal androgen exposure did not lead to
significant alterations in the hepatic IGF system. There were no
changes in IGF1 (Fig. 5H), IGFBP1 (Fig. 5I), or IGF1R
(C=0.05960.014 Vs TP=0.05160.017) gene expression.
Discussion
Epigenetic programming of reproductive and metabolic func-
tion in the adult through maternal androgenization of the fetus is
well documented [7,10,11,13,15], and has been likened to the
features common to PCOS in women [5,6]. In an ovine model of
midgestation androgenization, we investigate the metabolic and
hepatic consequences of both indirect maternal and direct fetal
androgenization in young adult sheep. The fetal androgenization
model is novel with direct injection of the fetus with depot TP, and
thus these effects can be compared with the fetal programming
effect of increased testosterone in the mother. As such this
treatment paradigm was performed in parallel to ewes receiving
maternal TP over a comparative gestational period to delineate
between the maternal impact of TP and any effects of placental
aromatization of androgens [25], with those of direct TP effects in
the fetus.
Fatty liver has not been previously reported in animal models of
PCOS, however, NAFLD incidence is increased in women with
PCOS and is associated with elevated aminotransferases, hyper-
androgenemia and central obesity [18,19,20,26,27]. Maternal
androgenization resulted in subclinical hepatic steatosis in young
sheep, which was not associated with increased central (omental)
fat, basal hyperinsulinemia or increased peripheral testosterone
concentrations. In clinical terms, liver damage was not discernable
as standard liver function tests, including ALT, AST, ALP and
GGT, remained normal. This model may therefore present a pre-
liver phenotype that is independent of the metabolic and
hormonal features of PCOS and that could develop further to a
detrimental metabolic consequence of prenatal androgenization,
similarly to the progression of the reproductive phenotype as the
animals age [8,28].
As these sheep showed evidence of pancreatic dysregulation it
remains unclear whether there is a temporal relationship or
association between the development of fatty liver and increased
insulin concentrations [29]. Hyperinsulinemia is a common
feature of PCOS that results from a pancreatic b-cell defect
[30], and can culminate in peripheral insulin resistance as the
phenotype develops in both non-obese and obese patients [24,31].
During intravenous GTT, insulin response to glucose load was
significantly increased in maternally androgenized animals,
implying a defect in pancreatic insulin secretion. While not a
direct measure of insulin sensitivity, these findings may suggest
reduced responsiveness of peripheral tissues to insulin and
subsequently an enhanced requirement for insulin secretion.
These animals did not appear to be glucose intolerant at this
stage since glucose clearance was unaffected. Previous studies have
shown that prenatal TP from d30–90 and/or d60–90 lead to
reduced insulin sensitivity in 5 week [15] and 11 week [14] old
lambs and that the critical developmental programming period for
insulin signaling is during d60–90 [14]. Additionally, these studies
reveal the parallel effects of prenatal TP and non-aromatizable
dehydrotestosterone (DHT) indicating an androgenic mode of
programming [14]. For technical reasons we were unable to
conduct a euglycemic clamp to directly measure insulin sensitivity,
however, our findings further underline intrinsic changes that
occur prior to alterations in body weight, fat distribution or
circulating androgen concentrations.
In parallel to investigating the programming effects of increased
androgens in the mother we also attempted to study the effects
directly in the fetus and analyze the same metabolic and hepatic
parameters as in the traditional model. Direct fetal exposure to TP
during the same treatment window did not alter the proportion of
young adults that had hepatic lipid accumulation, but remarkably
all animals, including the control cohort, presented physical signs
of fatty liver. No animals in this model presented with altered
central obesity, circulating androgen or insulin concentrations.
Interestingly, during GTT, insulin secretion in response to glucose
was raised in both treatment groups so that the mean value fell
mid-way between maternal control and TP groups. Epigenetic
programming arising as a direct result of this fetal treatment
intervention is of interest and might arise through maternal
anesthesia, the injection itself or the oil used the dilute the TP and
could therefore be a consequence of stress or inflammatory
induced pathways. While the underlying mechanisms leading to
these findings will require further interrogation, it appears that at
higher concentrations [32], for at least as long, of fetal androgens
did not program additional fatty liver changes. This is important
as it could imply that the changes observed in the maternal treated
cohort may not arise through the direct actions of androgens per se
and confirms that some features of prenatal androgenization
animal models of PCOS are not directly related to androgen
exposure [33,34,35].
Since these animals showed early signs of liver damage, a
comprehensive molecular analysis was carried out in these livers to
identify mechanistic pathways that might be altered. These
findings are discussed below and are summarized in Table 1 for
clarity. The finding of altered adult liver lipid composition in both
models prompted the investigation of hepatic modulators of
metabolism and glucose homeostasis. A candidate for study was
PEPCK, which in the liver catalyzes the conversion of oxaloac-
etate into phosphoenolpyruvate and is the rate limiting step of
gluconeogenesis [36]. Gluconeogenesis is an essential hepatic
process to maintain normal blood glucose concentrations. PEPCK
undergoes tight transcriptional control and can be regulated by
hormones, including insulin that has an inhibitory role and
glucagon and glucocorticoids that stimulate its expression [37].
Prenatal androgenization of the mother had no effect on hepatic
PEPCK expression in the adult offspring. However, direct fetal
treatment led to differential changes in PEPCK gene expression
with a significant upregulation in fetal control compared to
maternal control animals, but a downregulation in fetal TP
compared to fetal control cohorts. In this instance the fetal
injection phenotype was altered by direct exposure to androgens.
PEPCK has been linked to the development of fatty liver in mice.
Over-expression of PEPCK leads to a type II diabetic phenotype
[38], however liver-specific knock-out does not affect blood
glucose but does result in the development of fatty liver [39],
suggesting a role in liver lipid metabolism distinct from
gluconeogenesis [40,41]. The role and regulation of liver PEPCK
In Utero Programming of Metabolic Dysregulation
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it can be altered by fetal injection and modified by androgen
exposure in the fetus.
In addition to PEPCK, other gene candidates that have roles in
hepatic metabolic processes including MAP2K4 (ceramide signal-
ing), UGCG (ceramide metabolism) and ACADM (lipid metabolism)
were studied. These genes were selected as they are known to be
positively associated with fatty liver in human subjects [42].
MAP2K4 activates other MAP kinases to illicit downstream
signaling in response to stress, pro-inflammatory cues or mitogenic
stimuli and is essential for liver development in mice [43]. We
found a trend for increased MAP2K4 gene in livers from maternal
androgenized offspring, and a 4-fold up-regulation of hepatic
MAP2K4 in animals that were directly androgenized. The enzyme
UGCG catalyzes the initial glycosylation step of the synthesis of
glycosphingolipids, which are important cell membrane compo-
nents with varying cellular roles [44]. In our models, an
upregulation of UGCG observed in adult livers was programmed
by maternal androgens, and increased fetal androgens also
affected this gene expression in a similar trend. During lipid
metabolism, the first step of b-oxidation of fatty acids is catalyzed
by ACADM. In addition to being associated with NAFLD in gene
studies, increased serum b-hydroxybutyrate concentrations, as an
indirect measure of fatty acid oxidation, are present in patients
with fatty liver [45,46]. While not affected by maternal
androgenization, ACADM was also altered in an upward trend in
those animals directly receiving prenatal androgens. Unlike
PEPCK, these genes were not affected by injection paradigm and
appear to be upregulated as a response to androgens. These
findings indicate intrinsic molecular alterations occurring in the
liver prior to the clinical manifestation of liver damage.
Given that PCOS is a reproductive and metabolic disorder,
factors produced by the liver that could affect ovarian function as
well as metabolism, namely IGF1 and its signaling system, were
also studied. IGFBP1 sequesters IGF1 reducing bioavailability
[47] and an increased IGF1:IGFBP1 ratio [48] and reduced
IGFBP1 [49] in serum is associated with obesity, hyperinsulinemia
and insulin resistance in human studies and in women with PCOS
[50,51]. Hepatic IGF1 mRNA was significantly increased in
maternal androgenized offspring so that alterations in the hepatic
expression of IGF1 could be involved in the phenotype associated
with ovine prenatal androgenization [13,14,15]. Conversely, direct
androgenization of the fetus did not affect adult liver expression of
IGF1. It is however likely that steroids have a role in the
modulation of liver IGF1 expression. The human IGF1 gene is
known to contain androgen responsive elements in the upstream
promoter region that bind AR and stimulate IGF1 transcription
[52]. Although circulating testosterone concentrations were not
altered in these sheep, liver AR was upregulated after maternal
androgen exposure and therefore these livers may be more
responsive to androgens. Interestingly, AR gene expression in
controls was also increased as a consequence of fetal injection
paradigm and could therefore also enhance the receptivity of these
livers to androgens if mirrored by protein expression. Unfortu-
nately, due to the recognized technical limitations of Western
blotting for IGF1 or AR in ovine tissues, we were unable to
convincingly and robustly analyze expression at the protein level.
In addition to changes in hepatic AR gene expression other
alterations in hormone receptor expression were observed. These
included the upregulation of GR following maternal androgeniza-
tion, and differentially, the increase in ERa expression following fetal
exposure to androgens. It is not known what the significance of these
changes in potential hepatic receptivity to these steroid hormones is,
but illustrates further intrinsic perturbations in liver function and
signaling as a consequence of prenatal androgenization.
In an ovine model of prenatal maternal androgenization, we
report the occurrence of hepatic steatosis, alterations in hepatic
metabolic gene expression and perturbations in insulin secretion in
young adults. These changes are independent of central obesity
and hyperandrogenemia and may be the culmination of
disturbances to hepatic metabolic homeostasis predisposed by
exposure to in utero factors, including androgens, estrogens and/or
stress. Direct injection of a midgestation fetus results in the
universal development of fatty liver which suggests that some
effects are not entirely attributable to programming by TP.
Nevertheless, alterations in hepatic metabolic gene expression, as a
consequence of direct fetal exposure, did mirror that of maternal
androgen exposure. In a prenatal androgenization ovine model of
PCOS, these data suggest that: 1) aspects of metabolic disturbance
that occur in women with PCOS may be programmed before
birth and are independent of secondary metabolic and/or
hormonal modulators, and 2) androgens per se may not be directly
responsible for the epigenetic programming of all PCOS-like
features reported in offspring of androgenized mothers.
Materials and Methods
Ethics Statement
These studies were approved by the UK Home Office and were
conducted under an approved Project Licence (PIL 60/3744)
following review by the University of Edinburgh Animal Research
Ethics Committee.
Reagents
All reagents and chemicals were obtained from Sigma-Aldrich
(Poole, UK), unless otherwise stated.
Animal treatments and tissue collection
Scottish Greyface ewes were mated with Texel rams and
singleton, twin and triplet pregnancies were evenly divided
between treatment and control groups. Triplet pregnancies were
not included in the fetal injection cohort. In the maternal injection
cohort, pregnant ewes were treated intramuscularly twice weekly
Table 1. Summary of the effects of differing fetal
programming models on hepatic gene expression in the adult
ewe.
Gene
Maternal TP
Effect Fetal TP Effect
Fetal Injection
Effect
AR q* Qq
ERa - q*-
GR q*- -
PEPCK - Q* q*
MAP2K2 qq *-
UGCG q* q -
ACADM - q -
IGF1 q*- -
IGFBP1 - Q -
IGF1R q --
Upward arrows (q) represent an increase and downward arrows (Q) represent
a decrease in mean gene expression in TP cohorts compared to controls. The
fetal injection column is compared to the maternal controls. Asterisks (*)
indicate significantly altered gene expression. Dashes (-) represent no change.
doi:10.1371/journal.pone.0024877.t001
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Europe Ltd, Abingdon, UK), in vegetable oil, from d62–102 of
gestation (term is 147 days). In the fetal injection cohort, mothers
were anesthetized prior to fetal injection by initial sedation using
10 mg Xylazine (i.m.; Rompun; Bayor Plc Animal Health
Division, Berkshire, UK), followed by 2.0 mg/kg Ketamine (i.v.;
Keteset; Fort Dodge Animal Health, Southampton, UK). Ewes
were additionally administered a post-operative dose of antibiotics
(1 ml/25 kg; i.m.; Streptacare; Animalcare Ltd., York, UK).
Under sterile surgical conditions fetuses were injected at d62 and
d82 of gestation into the flank once with 0.2 ml vehicle C or
20 mg TP using a 20 G Quincke spinal needle (BD Biosciences,
Oxford, UK) under ultrasound guidance. The fetal injections were
timed to commence on the same day as maternal injection and
since we have previously shown that this TP depot is long-lasting
[32], two injections 20 days apart were selected to best mirror the
length of fetal exposure through maternal injections. Lambs were
weaned at 3 months and fed hay or grass ad libitum until 11 months
of age.
Adult female offspring numbers from maternal and fetal
treatment groups were C=5 and 4, and TP=9 and 7,
respectively. Animals were fasted and a GTT performed on the
day of sacrifice with bolus glucose (500 mg/ml in 20 ml)
administered intravenously following collection of a peripheral
basal blood sample. Blood was re-sampled after 15 min and the
animal immediately euthanized and tissue collected. Equivalent
liver samples were snap frozen and stored at 280 C, or embedded
in cassettes containing OCT compound (VWR International,
Poole, UK) and snap frozen, or stored in Bouins fixative for 24 h,
transferred to 70% ethanol and embedded in paraffin wax. In
addition, the omental fat was removed and weighed. Blood was
decanted into a heparinized test-tube for hormonal/metabolite
measurements or S-Monovettes containing sodium fluoride
combined with anti-coagulant (Sarstedt Ltd., Nu ¨mbrecht, Ger-
many) for glucose measurement. Tubes were centrifuged at
3000 rpm for 15 min at 4 C and the plasma collected and stored
at 220 C.
Measurement of glucose and insulin
Glucose concentrations were measured with a colorimetric
glucose assay kit (Alpha Laboratories Ltd., Eastleigh, UK), using a
Cobas Fara centrifugal analyzer (Roche Diagnostics Ltd., Welwyn
Garden City, UK). Assay sensitivity was 0.2 mmol/l and intra-
and inter-assay coefficient of variation (CVs) were ,2% and
,3%, respectively. Insulin was measured using an ovine insulin
ELISA kit (80-INSOV-E01, ALPCO Diagnostics, Salem, NH,
USA) as per the manufacturer’s instructions. Absorbance was
measured colorimetrically on a ThermoMax Microplate Reader
(Molecular Devices, CA, USA) at 450 nm with a reference
wavelength of 650 nm. A standard curve comprising a cubic spline
fit was generated and insulin concentrations calculated using
SoftMax Pro software (Molecular Devices). Assay sensitivity was
5.0 pg/ml and intra- and inter-assay CVs were ,5% and ,6%,
respectively.
Measurement of other plasma analytes
To measure the concentration of cholesterol, triglycerides, FFA,
ALT, AST, ALP and GGT, commercial assay kits were employed
(Alpha Laboratories Ltd., Eastleigh, UK) as per the manufactur-
er’s protocols, using a Cobas Fara centrifugal analyzer (Roche
Diagnostics Ltd.) to obtain analyte concentration. Assay sensitiv-
ities for cholesterol, FFA, triglycerides, ALT, AST, ALP and GGT
were 0.1 mmol/l, 0.05 mmol/l, 0.02 mmol/l, 4 U//l, 6 U/l,
20 U/l and 5 U/l, respectively, and the overall CVs were all
,3%. Serum leptin concentrations were obtained using a Multi-
Species Leptin radioimmunoassay kit with an antibody against
human leptin (XL-85K, Millipore, Missouri, USA). Assay
sensitivity was 1.0 ng/ml and intra- and inter-assay CVs were
,4% and ,7%, respectively. Serum testosterone concentrations
were measured using an in-house radioimmunoassay method
described previously [53,54], where the intra- and inter-assay CVs
were ,10% and assay sensitivity 12 pg/ml.
Table 2. Forward and reverse primer sequences, product
sizes and accession numbers for genes analyzed by qRT-PCR.
bp: base pairs.
Gene (accession) Nucleotide Sequence (59–39)
Product
size (bp)
AR (XM_001253942)
Forward GCCCATCTTTCTGAATGTCC 233
Reverse CAAACACCATAAGCCCCATC
ERa (NM_001001443)
Forward GAATCTGCCAAGGAGACTCG 187
Reverse CCTGACAGCTCTTCCTCCTG
GR (NM_001114186)
Forward AAGTCATTGAACCCGAGGTG 207
Reverse ATGCCATGAGGAACATCCAT
MAP2K4 (NM_001099038)
Forward CAGCATTGAGTCGTCAGGAA 234
Reverse TCACTGCTCCGCATCACTAC
UGCG (NM_001076850)
Forward GGAGGTTTGCAATGTCCACT 157
Reverse CTGGCAACAAAGCATTCTGA
ACADM (NM_001075235)
Forward AACCTGTAGCAGGCTCTGATG 209
Reverse TACTCCTGGGGTGTCTGCTT
IGF1 (NM_001009774)
Forward CATCCTCCTCGCATCTCTTC 239
Reverse CTCCAGCCTCCTCAGATCAC
IGF1R (XM_002696504)
Forward CCAAAACCGAAGCTGAGAAG 199
Reverse TCCGGGTCTGTGATGTTGTA
IGFBP1 (NM_001145177)
Forward TCCCCAGAGAGCTCAGAGAT 207
Reverse CTGCTCCCTGGCTAATCTGT
PEPCK (NM_174737)
Forward AAAGAGATACGGTGCCCATC 178
Reverse ATGCCAATCTTGGACAGAGG
SHBG (NM_001098858)
Forward ACTTGGGATCCAGAGGGAGT 208
Reverse CCACCCTGAGTAGCAAGGAA
GAPDH (NM_001034034)
Forward GGCGTGAACCACGAGAAGTATAA 229
Reverse AAGCAGGGATGATGTTCTGG
doi:10.1371/journal.pone.0024877.t002
In Utero Programming of Metabolic Dysregulation
PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24877Oil Red O Lipid Staining and Analysis
Frozen 5 mm sections from OCT embedded liver samples were
cut (Leica Cryostat Microtome 1900, Leica Biosystems Nussloch
GmbH, Heidelberger, Germany) at 220 C, mounted onto glass
slides and air dried. Tissue was fixed in 10% formalin for 10 min,
rinsed in distilled water (dH20) and air dried before a further rinse
in 60% isopropanol. Sections were stained with Oil Red O
dissolved in 60% isopropanol for 15 min at room temperature and
rinsed in 60% isopropanol followed by washing in dH20. Tissue
was counterstained in hematoxylin, washed thoroughly in dH20
and mounted in Aqua-Mount media (Thermo Fisher Scientific,
Loughborough, UK). Unsaturated hydrophobic lipids were
identified microscopically by the presence of a red stain and was
subsequently quantified blindly by two independent investigators
by classification into negative (-), possible early (2/+) and positive
(+) fatty liver categories by comparison to pre-agreed reference
sections.
Quantitative (q)RT-PCR
RNA was extracted from a whole frozen liver sample using the
TRI reagent method. Briefly, tissue was homogenized in 1 ml TRI
reagent using a Qiagen TissueLyser (Qiagen Ltd., West Sussex,
UK), rested for 5 min and phase separated with the addition of
0.2 ml chloroform and vigorous shaking for 15 sec. Samples were
incubated for 5 min at room temperature and centrifuged at
12,000 g at 4 C for 20 min. The upper aqueous phase containing
RNA was collected, mixed with 0.5 ml isopropanol, and incubated
for 10 min at room temperature. Samples were centrifuged at
12,000 g at 4 C for 15 min and the RNA pellet washed in 1 ml
75% ethanol prior to centrifugation at 7,500 g and 4 C for a
further 10 min. The pellet was subsequently air dried before
elution in 50 mL nuclease-free water and stored at 280 C. RNA
concentration and purity were measured using a NanoDrop 1000
spectrophotometer (Thermo Fisher Scientific) and cDNA was
synthesized from 200 ng total RNA using the High Capacity
cDNA reverse transcription kit (Applied BioSystems, CA, USA)
and stored at 220 C.
Forward and reverse primers were designed for qRT-PCR
(Table 2) using Primer3 Input v0.4 software [55]. Conventional
PCR and PCR-product DNA sequencing was performed for
validation of authenticity of the gene product in the sheep. Primer
efficiency and suitability for SYBR Green qRT-PCR was further
validated through generation of standard curves in qRT-PCR
reactions. A 10 mL final reaction volume was prepared with Power
SYBR Green PCR Master Mix (1X; Applied BioSystems), pre-
diluted primer sets (0.5 mM), cDNA (1 mL) and nuclease-free
water, with all reactions carried out in duplicate. The thermal
cycling program included a denaturing step (95 C for 10 min),
combined annealing and extension step (95 C for 15 sec, 60 C for
1 min [x40]), and a final dissociation step (95 C, 60 C and 95 C for
15 sec each). Negative controls per gene consisted of the use of
cDNA prepared minus reverse transcriptase, and omission of
cDNA from the qRT-PCR reaction. The expression of the
unknown target gene relative to glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) as an internal control was quantified
using the DCt method.
Immunohistochemistry
Immunohistochemistry was performed on 5 mm liver sections
using AR and PEPCK antibodies. Tissue sections were dewaxed
and rehydrated prior to antigen retrieval by pressure cooking
(0.01 M sodium citrate buffer pH 6.0) for 5 min. Sections were
washed (265 min) in phosphate buffered saline (PBS), incubated
in 3% H2O2 for 10 min, followed by further PBS washes
(265 min). Endogenous avidin/biotin sites were blocked to
prevent non-specific antibody binding using the Avidin/Biotin
Blocking Kit as per the manufacturer’s instructions (Vector
Laboratories, Peterborough, UK). Sections were incubated with
blocking serum; 20% normal goat serum/5% bovine serum
albumin/PBS, for 1 h. Primary antibodies; AR (1:100, N20 rabbit
polyclonal rabbit sc-816, Santa Cruz Biotechnology Inc., Santa
Cruz, USA) or PEPCK (1:100, H300 rabbit polyclonal sc-32879,
Santa Cruz Biotechnology Inc.) were diluted in the blocking serum
and applied to tissue overnight at 4 C.
Tissue sections were washed in PBST (PBS +1% tween;
265 min) before incubation with a biotinylated goat anti-rabbit
IgG (1:500, Dako, Glostrup, Denmark). After 265 min PBS
washes, Vectastain ABC Elite tertiary complex (PK-1600 Series,
Vector Laboratories) was applied for 1 h, and the tissue washed
265 min in PBS. Staining was visualized colorimetrically by
application of 3,39-diaminobenzidine (Dako) for 30 sec. Tissue was
rinsed in dH20, dehydrated, counterstained with hematoxylin and
mounted. Negative controls consisted of incubation with a non-
specific rabbit IgGs and omission of the primary antibody.
Statistical analysis
Statistical analyses were performed with Graph Pad Prism v4.0
(GraphPad Software Inc., San Diego, CA, USA). An unpaired
Student’s t-test, or a Mann Whitney non-parametric test was
applied when group variances were not equal or the data was not
normally distributed, to compare the means of two groups. A chi-
squared test was employed when analyzing proportional data. P-
values of P,0.05 were regarded as significant.
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